• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Grace Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    9/12/25 4:13:10 PM ET
    $GRCE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRCE alert in real time by email
    false0001444192DE00014441922025-09-122025-09-12

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): September 12, 2025

    GRACE THERAPEUTICS, INC.
    (Exact name of registrant as specified in its charter)

    State of Delaware
    001-35776
    98-1359336
    (State or Other Jurisdiction of Incorporation)
    (Commission File Number)
    (IRS Employer Identification No.)

    103 Carnegie Center
    Suite 300
    Princeton, New Jersey
     
    08540
    (Address of Principal Executive Offices)
     
    (Zip Code)
     
    Registrant’s telephone number, including area code: (609) 322-1602

    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
     
    Trading Symbol(s)
     
    Name of each exchange on which registered
    Common Stock, par value $0.0001 per share
     
    GRCE
     
    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐



    Item 5.07
    Submission of Matters to a Vote of Security Holders.

    On September 12, 2025, Grace Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Meeting”). Proxies for the Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition to the Company’s board of director’s solicitation. Stockholders of a total of 7,926,945 of the Company’s shares of common stock were present or represented by proxy at the Meeting, representing 57.32% of the Company’s 13,828,562 shares of common stock issued and outstanding and entitled to vote at the Meeting as of the record date of July 18, 2025. Set forth below are the matters acted upon by the Company’s stockholders at the Meeting and the final voting results on each matter. Each of the proposals is described in further detail in the Proxy Statement.

    Proposal No. 1 – Election of Directors

    The nominees listed below were elected as directors by the following votes to serve until the close of the Company’s next annual meeting of stockholders and until such director’s successor is elected and qualified or until his earlier death, resignation, retirement, disqualification or removal:

    Nominee
     
    Votes For
     
    Withheld
     
    Broker Non-Votes
    Vimal Kavuru
     
    6,294,270
     
    34,185
     
    1,598,490
    A. Brian Davis
     
    6,299,935
     
    28,520
     
    1,598,490
    Prashant Kohli
     
    6,299,420
     
    29,035
     
    1,598,490
    S. George Kottayil
     
    6,300,168
     
    28,287
     
    1,598,490
    Edward Neugeboren
     
    6,300,263
     
    28,192
     
    1,598,490

    Proposal No. 2 – Advisory Vote to Approve Named Executive Officer Compensation

    The proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s proxy statement was approved by the stockholders by the following vote:

    For
     
    Against
     
    Abstain
     
    Broker Non-Votes
    6,178,757
     
    74,002
     
    75,696
     
    1,598,490

    Proposal No. 3 – Ratify the Appointment of Independent Registered Public Accounting Firm
     
    The proposal to ratify the appointment KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending March 31, 2026 was approved by the stockholders by the following vote:
     
    For
     
    Against
     
    Abstain
     
    Broker Non-Votes
    7,797,832
     
    127,248
     
    1,865
     
    0


    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    Date:  September 12, 2025 GRACE THERAPEUTICS, INC.
       
     
    By:
    /s/ Prashant Kohli
     
    Name: Prashant Kohli
      Title:   Chief Executive Officer



    Get the next $GRCE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GRCE

    DatePrice TargetRatingAnalyst
    5/2/2025$12.00Buy
    TD Cowen
    More analyst ratings

    $GRCE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Grace Therapeutics with a new price target

    TD Cowen initiated coverage of Grace Therapeutics with a rating of Buy and set a new price target of $12.00

    5/2/25 8:14:37 AM ET
    $GRCE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRCE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $GRCE
    SEC Filings

    View All

    $GRCE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting

    PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for I.V. infusion to address significant unmet medical needs in aSAH patients, today announced that results from its Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH (the STRIVE-ON trial–NCT05995405) were presented at the 2025 Neurocritical Care Society annual meeting, held in Montreal, Quebec, Canada September 18-21, 2025. In an oral presentation titled Safety and Tolerability of GTx-104 (Nimodipine Injection for I.V. Infusion

    9/22/25 8:00:00 AM ET
    $GRCE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104

    Grant of First Method of Use Patent Adds New Pillar to Grace's Multi-layered Intellectual Property and Potential Market Exclusivity Protection Patent Coverage Extended to 2043 PRINCETON, N.J., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for I.V. infusion to address significant unmet medical needs in aSAH patients, today announced that the U.S. Patent and Trademark Office has issued a U.S. Patent No. 12,414,943, titled "Nimodipine Parenteral Administration". The new method of use patent, publ

    9/18/25 8:30:00 AM ET
    $GRCE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference

    PRINCETON, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that it will be featured as a presenting company at the H.C. Wainwright 27th Annual Global Investment Conference, being held virtually and in person September 8–10, 2025. The event will take place at the Lotte New York Palace Hotel in New York City. Virtual participation will be staged simultaneously, with more than 550 company presentations sch

    9/4/25 8:00:00 AM ET
    $GRCE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Grace Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Grace Therapeutics, Inc. (0001444192) (Filer)

    9/18/25 8:43:32 AM ET
    $GRCE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Grace Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Grace Therapeutics, Inc. (0001444192) (Filer)

    9/12/25 4:13:10 PM ET
    $GRCE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Grace Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Grace Therapeutics, Inc. (0001444192) (Filer)

    8/27/25 8:08:12 AM ET
    $GRCE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Kottayil George

    4 - Grace Therapeutics, Inc. (0001444192) (Issuer)

    5/13/25 5:21:16 PM ET
    $GRCE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Davis A Brian

    4 - Grace Therapeutics, Inc. (0001444192) (Issuer)

    5/13/25 5:21:13 PM ET
    $GRCE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Kavuru Vimal

    4 - Grace Therapeutics, Inc. (0001444192) (Issuer)

    5/13/25 5:21:11 PM ET
    $GRCE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRCE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Grace Therapeutics Inc.

    SC 13G/A - Grace Therapeutics, Inc. (0001444192) (Subject)

    11/14/24 4:40:44 PM ET
    $GRCE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Grace Therapeutics Inc.

    SC 13G/A - Grace Therapeutics, Inc. (0001444192) (Subject)

    11/14/24 11:58:16 AM ET
    $GRCE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GRCE
    Leadership Updates

    Live Leadership Updates

    View All

    Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

    BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the "Effective Date"). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. "We are thrilled to announce the addition of Keith and Edward to our Board," stated Jerome D. Jabbour, Chief Executive Officer of Matinas. "Their deep industry experience, leadership expertise, and capital markets acumen will be of great value as we move the company forward into a new era continu

    3/11/25 7:00:00 AM ET
    $GRCE
    $MTNB
    $ONVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)